US Must Rethink Biologic Naming Suffix, Says IGBA

In the wake of a decision by Health Canada not to implement a suffix to non-proprietary names to distinguish biosimilars from their branded counterparts, the IGBA has urged the FDA to reconsider the US approach.

LightBulb
An Increasingly Isolated US Is Urged To Rethink Its Biologic Naming Approach • Source: Shutterstock

More from Biosimilars

More from Products